

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	ocriplasmin
Brand Name	Jetrea®
Dosage Form(s)	Single-use vial containing 0.5 mg in 0.2 mL solution for intravitreal injection (2.5 mg/mL)
Manufacturer	Alcon Canada Inc.
Submission Review	New Submission
Use Reviewed	symptomatic vitreomacular adhesion (VMA)
Common Drug Review (CDR)	CDR recommended to: List with criteria. Visit CADTH website for criteria details: http://www.cadth.ca/media/cdr/complete/SR0337_complete_Jetrea_Dec-23-13.pdf
Provincial Review	Medical Beneficiary and Pharmaceutical Services Division, Ministry of Health reviewed and considered various inputs including: the final review completed by the Common Drug Review (CDR) on December 20, 2013 which included clinical and pharmacoeconomic evidence and the recommendation from the Canadian Drug Expert Committee (CDEC), as well as clinical practice input from the BC retinal specialists, and a Budget Impact Assessment.
Drug Coverage Decision	Limited Coverage Benefit http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/ocriplasmin.html
Date	January 27, 2015
Reason(s)	<ul style="list-style-type: none"> Based on the CDR clinical evidence and pharmacoeconomic reports, the review concluded the drug is beneficial as a non-surgical treatment option for a small subset of the patients with symptomatic VMA (specifically those meeting the criteria defined by CDR). Based on economic considerations and the product price, the drug is cost effective. The listing decision aligns with the Canadian Drug Expert Committee (CDEC) Common Drug Review recommendation for ocriplasmin.
Other Information	None